CD274 and sarcoma: In sarcomas, IDO-1 targeting has been addressed in a publication where the IDO-1 expression was significantly correlated with high CD8+ infiltration, but no antitumoral activity was found with the combination of IDO inhibitor plus PD-L1 blockade [208].